Showing 6801-6810 of 8469 results for "".
- New INTEGUMENT-PED Results Support Roflumilast Cream for Pediatric ADhttps://practicaldermatology.com/news/phase-3-trial-supports-roflumilast-cream-for-young-children-with-ad/2471293/Arcutis Biotherapeutics announced today that the INTEGUMENT-PED Phase 3 trial had met its primary endpoint, according to a release from the manufacturer. Researchers on the study evaluated the efficacy and safety of roflumilast cr
- Analysis: Sustained Eczema and Psoriasis Remission Achieved with Dupilumabhttps://practicaldermatology.com/news/analysis-sustained-eczema-and-psoriasis-remission-achieved-with-dupilumab/2471286/A new study highlights the potential of dupilumab to deliver sustained remission in children with moderate-to-severe atopic dermatitis (AD). The findings, presented as a poster at the 2025 Masterclasses in Dermatology conference
- Bill Collection Made Tougher by Recent Changes in Credit Reportinghttps://practicaldermatology.com/news/Bill-Collection-Made-Tougher-Recent-Changes-Credit-Reporting/2471259/Americans owe $220 billion in medical debt,1 and the most effective method for collecting money could soon cease to be an option. Mark Nestor, MD, PhD, highlighted this issue during a presentation at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii. “Ba
- Patient-Centric Guidelines for Generalized Pustular Psoriasis Management Unveiledhttps://practicaldermatology.com/news/patient-centric-guidelines-for-generalized-pustular-psoriasis-management-unveiled/2471251/A global Delphi study has established holistic treatment goals for generalized pustular psoriasis (GPP), integrating both physician and patient perspectives. The consensus study included participants from 24 countries, and acc
- Dr. Siegel Discusses Sedation Without Drugshttps://practicaldermatology.com/news/Dr-Siegel-Discusses-Sedation-Without-Drugs/2471217/A significant portion of today’s patient population is interested in all-natural alternatives to drugs when possible, and sedation is an area where some useful options exist, according to Daniel M. Siegel, MD. “Sedation without drugs [is important] if you have new-age patients or, I guess,
- Dr. Armstrong Discusses Combination Therapies for Psoriasishttps://practicaldermatology.com/news/Dr-Armstrong-Discusses-Combination-Therapies-Psoriasis/2471212/The quality and variety of biologic therapeutic options available today should give dermatologists more confidence than ever in treating psoriasis, according to April Armstrong, MPH, MPH. Speaking at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, Dr. Armstrong discuss
- 2% Medicare Payment Increase Could Be Imminenthttps://practicaldermatology.com/news/2-Medicare-Payment-Increase-Could-Be-Imminent/2471172/A 2% payment increase for physicians from Medicare appears close after American Academy of Dermatology (AAD) president Seemal Desai, MD, FAAD, attended a congressional session on February 11. “This bill has so much momentum that we are finally on the cusp,” Dr. Desai said during an AAD upd
- Nemolizumab Approved by European Commission for Moderate-to-severe Prurigo Nodularishttps://practicaldermatology.com/news/nemolizumab-approved-european-commission-for-moderate-to-severe-prurigo-nodularis/2471164/Nemolizumab has been approved by the European Commission for the treatment of moderate-to-severe prurigo nodularis, according to an announcement from Galderma. The approval of the monoclonal antibody (marketed as Nemluvio) fol
- Galderma Renews Sensitive Skin Care Research Fund at GWhttps://practicaldermatology.com/news/galderma-renews-sensitive-skin-care-research-fund-at-gw/2471114/Galderma extended its partnership with the Department of Dermatology at the George Washington University (GW) School of Medicine and Health Sciences (SMHS) by renewing the Sensitive Skin Care Research Acceleration Fund to support efforts to redefine the understanding and management of this
- New Dupilumab Data for CSU to Be Presented at AAAAI Meetinghttps://practicaldermatology.com/news/New-Dupilumab-Data-CSU-Be-Presented-AAAAI-Meeting/2471105/New phase 3 data on dupilumab for chronic spontaneous urticaria (CSU) will be among 24 abstracts presented by Sanofi at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in San Diego, California, from February 28 to March 3. The dupilumab CSU data from the LIBER